In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv

被引：66
作者：
Ahmad, Z [1 ]
Sharma, S [1 ]
Khuller, GK [1 ]
机构：
[1] Postgrad Inst Med Educ & Res, Dept Biochem, Chandigarh 160012, India
来源：
FEMS MICROBIOLOGY LETTERS | 2005年 / 251卷 / 01期
关键词：
clotrimazole; econazole; antitubercular drugs; mycobacteria;
D O I：
10.1016/j.femsle.2005.07.022
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The antimycobacterial activity of two clinically approved antifungal azole drugs, clotrimazole and econazole, was evaluated against Mycobacterium tuberculosis H(37)Rv under in vitro and ex vivo conditions. The minimum inhibitory concentration (MIC90) was 0.120 mu g ml(-1), whereas the minimum bactericidal concentration and effective concentration was 0.125 mu g ml(-1) for both the drugs demonstrating their potent antimycobacterial activity. Further, the azole drugs exhibited a synergistic activity with either rifampicin or isoniazid as evaluated on the basis of reduction of colony forming units. The results suggest that azole compounds bear the potential to enhance the efficacy of currently prescribed antitubercular drugs. (c) 2005 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码：19 / 22
页数：4
相关论文
共 10 条
  • [1] Comparison of the toxicity of fluconazole and other azole antifungal drugs to murine and human granulocyte-macrophage progenitor cells in vitro
    Benkö, I
    Hernádi, F
    Megyeri, A
    Kiss, A
    Somogyi, G
    Tegyey, Z
    Kraicsovits, F
    Kovács, P
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (05) : 675 - 681
  • [2] Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling
    Betts, JC
    Lukey, PT
    Robb, LC
    McAdam, RA
    Duncan, K
    [J]. MOLECULAR MICROBIOLOGY, 2002, 43 (03) : 717 - 731
  • [3] COLIN J, 2000, FEMS MICROBIOL LETT, V192, P159
  • [4] Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis:: implications for treatment of tuberculosis
    Guardiola-Diaz, HM
    Foster, LA
    Mushrush, D
    Vaz, ADN
    [J]. BIOCHEMICAL PHARMACOLOGY, 2001, 61 (12) : 1463 - 1470
  • [5] Hartman PG, 1997, CURR PHARM DESIGN, V3, P177
  • [6] Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy
    Kalita, A
    Verma, I
    Khuller, GK
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (08) : 1476 - 1480
  • [7] LEONID BH, 1998, AM REV RESPIR DIS, V137, P711
  • [8] Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes
    McLean, KJ
    Marshall, KR
    Richmond, A
    Hunter, IS
    Fowler, K
    Kieser, T
    Gurcha, SS
    Besra, GS
    Munro, AW
    [J]. MICROBIOLOGY-SGM, 2002, 148 : 2937 - 2949
  • [9] MICHAEL JH, 2004, J ANTIMICROB CHEMOTH, V53, P185
  • [10] An ex vivo culture model for screening drug activity against in vivo phenotypes of Mycobacterium tuberculosis
    Turner, DJ
    Hoyle, SL
    Snewin, VA
    Gares, MP
    Brown, IN
    Young, DB
    [J]. MICROBIOLOGY-SGM, 2002, 148 : 2929 - 2936
1